Immunotherapy with chemotherapy before radiation for nasopharyngeal cancer
Part of Cancer, Ear, nose & throat, Mouth & dental clinical trials.
This trial tests a combination of chemotherapy (three drugs: docetaxel, cisplatin, and fluorouracil) plus an immunotherapy drug (a PD-1 inhibitor, which helps your immune system fight cancer) given before the standard radiation treatment for nasopharyngeal cancer. The goal is to see if this upfront treatment can improve outcomes in patients whose cancer has not spread to distant parts of the body.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have a specific type of nasopharyngeal cancer that is locally advanced (it has spread beyond the nasopharynx but not to distant organs).
- You have not had any prior treatment for this cancer.
- You are in generally good physical condition (able to do light work or be up and about).
- Your blood counts, liver, and kidney function are within normal limits.
- You do not have an active autoimmune disease, active hepatitis B or C, or a history of other cancers (except very early stage treated ones).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of immunotherapy (JS001) and chemotherapy (PFLL) versus a standard regimen (GP) for people with nasopharyngeal cancer that has spread. The goal is to see if the new combination works better at controlling the disease.
This trial tests a new treatment plan for a specific type of advanced nasopharyngeal cancer. It combines chemotherapy and radiation to see if it can improve outcomes for people with high-risk stage III disease.
This trial tests whether adding chemotherapy before the usual radiation and chemotherapy treatment can improve outcomes for people with a certain type of nasopharyngeal cancer that has higher risk features. It aims to see if the extra treatment helps control the cancer better.
This trial tests combining induction chemotherapy and immunotherapy with radiation, with or without additional chemotherapy, for patients with advanced nasopharyngeal cancer (throat cancer). It aims to see if adding chemotherapy during radiation improves outcomes compared to not having it.
This trial tests a combination of two types of radiation therapy (standard SBRT and low-dose radiation) along with chemotherapy and an immunotherapy drug (PD-1 antibody) for people whose nasopharyngeal cancer has come back or spread. The goal is to see if this combination can better control the cancer.
This trial tests whether a lower dose of radiation can safely treat stage III nasopharyngeal cancer if you have already responded well to initial chemotherapy plus immunotherapy (Camrelizumab). The goal is to reduce side effects while still controlling the cancer.
Hear when a new Immunotherapy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.